



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER ENDED 30 JUNE 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

CONDENSED CONSOLIDATED INCOME STATEMENTS FOR THE PERIOD ENDED 30 JUNE 2010

	Note	3 MONTHS ENDED		PERIOD ENDED	
		30/06/2010	30/06/2009	30/06/2010	30/06/2009
		RM'000	RM'000	RM'000	RM'000
Revenue	9	77,117	69,920	154,651	140,198
Cost of sales		(57,025)	(53,329)	(113,464)	(106,242)
Gross profit		20,092	16,591	41,187	33,956
Other income		423	227	686	582
Selling & marketing expenses		(9,933)	(8,786)	(19,366)	(17,468)
Administrative expenses		(3,388)	(2,982)	(6,881)	(5,892)
Other expenses		(12)	(178)	(153)	(354)
Finance cost		(88)	(157)	(171)	(374)
Share of results of associates		733	876	1,373	1,072
Profit before tax	9	7,827	5,591	16,675	11,522
Income tax expense	21	(1,778)	(1,029)	(3,708)	(2,685)
Net profit for the period		6,049	4,562	12,967	8,837
Attributable to:					
Equity holders of the Company		5,800	4,216	12,504	8,445
Minority interest		249	346	463	392
Net profit for the period		6,049	4,562	12,967	8,837
Earnings per share attributable to equity holders of the Company:					
		<u>Sen</u>	<u>Sen</u>	<u>Sen</u>	<u>Sen</u>
- Basic	30	6.19	5.62	13.34	11.26
- Diluted	30	6.19	5.62	13.34	11.26

The Condensed Consolidated Income Statements should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the Interim Financial Report.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER ENDED 30 JUNE 2010

(THE FIGURES HAVE NOT BEEN AUDITED)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 30 JUNE 2010

	3 MONTHS ENDED		PERIOD ENDED	
	30/06/2010	30/06/2009	30/06/2010	30/06/2009
	RM'000	RM'000	RM'000	RM'000
Net profit for the period	6,049	4,562	12,967	8,837
Other comprehensive income / (expense)				
Deferred tax on revaluation reserve	-	-	(33)	-
Total comprehensive income for the period	6,049	4,562	12,934	8,837
Attributable to:				
Equity holders of the Company	5,800	4,216	12,471	8,445
Minority interest	249	346	463	392
Total comprehensive income for the period	6,049	4,562	12,934	8,837

The Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the Interim Financial Report.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER ENDED 30 JUNE 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2010

		<u>Audited</u>
	As at	As at
Note	30/06/2010	31/12/2009
	RM'000	RM'000
ASSETS		
Non-Current Assets		
Property, plant and equipment	10 67,505	66,710
Investment properties	4,128	3,800
Intangible assets	1,291	1,405
Investment in associates	2 33,389	35,791
Available-for-sale investment	2 3,928	-
Deferred tax assets	243	58
	<u>110,484</u>	<u>107,764</u>
Current Assets		
Inventories	42,025	41,562
Trade and other receivables	26 77,422	67,704
Deposits, bank and cash balances	19,640	19,950
	<u>139,087</u>	<u>129,216</u>
TOTAL ASSETS	<u>249,571</u>	<u>236,980</u>
LIABILITIES		
Current Liabilities		
Trade and other payables	26 53,820	47,336
Borrowings	25 2,395	2,798
Current tax payable	3,958	1,572
	<u>60,173</u>	<u>51,706</u>
Non-Current Liabilities		
Borrowings	25 7,809	8,943
Deferred tax liabilities	4,509	3,948
	<u>12,318</u>	<u>12,891</u>
TOTAL LIABILITIES	<u>72,491</u>	<u>64,597</u>
NET ASSETS	<u>177,080</u>	<u>172,383</u>
EQUITY		
Equity attributable to equity holders of the Company		
Share capital	7 93,717	74,974
Reserves	7,155	12,493
Retained earnings	65,910	75,081
	<u>166,782</u>	<u>162,548</u>
Minority interest	10,298	9,835
TOTAL EQUITY	<u>177,080</u>	<u>172,383</u>
	RM	RM
Net Assets per share attributable to ordinary equity holders of the Company	<u>1.78</u>	<u>2.17</u>

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the Interim Financial Report.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER ENDED 30 JUNE 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 30 JUNE 2010

	Note	<u>Non-Distributable</u>			<u>Distributable</u>		Minority Interests	Total Equity
		Share Capital	Share Premium	Revaluation & other reserves	Retained Profits	Total		
		RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
<u>PERIOD ENDED 30 JUNE 2010</u>								
Balance as at 1 January 2010		74,974	5,305	7,188	75,081	162,548	9,835	172,383
Net profit for the 6-months period		-	-	-	12,504	12,504	463	12,967
Other comprehensive income/(expense)		-	-	(33)	-	(33)	-	(33)
Total comprehensive income/(expense)		-	-	(33)	12,504	12,471	463	12,934
Issue of bonus shares	7	18,743	(5,305)	-	(13,438)	-	-	-
Share issue expenses		-	-	-	(84)	(84)	-	(84)
Dividends	8	-	-	-	(8,153)	(8,153)	-	(8,153)
Balance as at 30 June 2010		93,717	-	7,155	65,910	166,782	10,298	177,080
<u>PERIOD ENDED 30 JUNE 2009</u>								
Balance as at 1 January 2009		74,974	5,305	3,992	58,419	142,690	7,430	150,120
Net profit for the 6-months period		-	-	-	8,445	8,445	392	8,837
Other comprehensive income/(expense)		-	-	-	-	-	-	-
Total comprehensive income/(expense)		-	-	-	8,445	8,445	392	8,837
Dividends	8	-	-	-	(2,530)	(2,530)	-	(2,530)
Balance as at 30 June 2009		74,974	5,305	3,992	64,334	148,605	7,822	156,427

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the Interim Financial Report.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER ENDED 30 JUNE 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE PERIOD ENDED 30 JUNE 2010

	PERIOD ENDED	
	30/06/2010	30/06/2009
	RM'000	RM'000
Cash flows from operating activities		
Profit before tax	16,675	11,522
Adjustments:		
Depreciation and amortization	3,071	3,188
Net profit on disposal of property, plant and equipment	(137)	(138)
Share of results of associates	(1,373)	(1,072)
Other non-cash items	384	2,374
Operating profit before working capital changes:	18,620	15,874
Inventories and receivables	(10,337)	(5,884)
Payables	6,477	5,313
Cash generated from operations	14,760	15,303
Tax paid	(1,227)	(1,518)
Net cash generated from operating activities	13,533	13,785
Cash flows from investing activities		
Dividends received from associate	-	500
Purchase of property, plant and equipment & intangible assets	(4,122)	(1,571)
Proceeds from disposal of property, plant and equipment	137	144
Interest received	87	44
Net cash used in investing activities	(3,898)	(883)
Cash flows from financing activities:		
Term loans repaid	(1,421)	(1,498)
Dividends paid	(8,153)	(2,530)
Share issue expenses paid	(84)	-
Other financing activities paid	(287)	(2,183)
Net cash used in financing activities	(9,945)	(6,211)
Net (decrease)/increase in cash and cash equivalents	(310)	6,691
Cash and cash equivalents at the beginning of the financial period	19,950	5,711
Currency translation difference	-	-
Cash and cash equivalents at the end of the financial period	19,640	12,402

The Condensed Consolidated Statement of Cash Flow should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the Interim Financial Report.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER ENDED 30 JUNE 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 JUNE 2010

1 Basis of Preparation and Accounting policies

The interim financial report has been prepared under the historical cost convention except for the following assets and liabilities which are stated at fair values: properties included within property, plant and equipment as disclosed in note 10, investment properties, and derivatives. The Interim Financial Report is unaudited and has been prepared in compliance with FRS No.134, "Interim Financial Reporting" and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad. It should be read in conjunction with the Group's most recent audited financial statements for the year ended 31 December 2009.

The significant accounting policies adopted are consistent with those adopted in the audited financial statements for the year ended 31 December 2009, except for the adoption of the following Financial Reporting Standards ("FRS") and Issues Committee ("IC") Interpretations:

FRS 7: Financial Instruments: Disclosures

FRS 8: Operating Segments

FRS 101: Presentation of Financial Statements (revised)

FRS 123: Borrowing Costs

FRS 139: Financial Instruments: Recognition and Measurement

Amendments to FRS 1: First-time Adoption of Financial Reporting Standards and FRS 127: Consolidated and Separate Financial Statements: Cost of an Investment in a Subsidiary, Jointly Controlled Entity or Associate

Amendments to FRS 132: Financial Instruments: Presentation

Amendments to FRS 139: Financial Instruments: Recognition and Measurement, FRS 7: Financial Instruments: Disclosures and IC Interpretation 9: Reassessment of Embedded Derivatives

Amendments to FRSs 'Improvements to FRSs (2009)'

IC Interpretation 9: Reassessment of Embedded Derivatives

IC Interpretation 10: Interim Financial Reporting and Impairment

IC Interpretation 11: FRS 2 - Group and Treasury Share Transactions

IC Interpretation 13: Customer Loyalty Programmes

IC Interpretation 14: FRS 119 - The Limit on a Defined Benefit Asset, Minimum Funding Requirements and their Interaction

The adoption of the above standards, amendments and interpretations do not have any material impact on the financial statements of the Group except for the adoption of the following standards:

The revised FRS 101 separates owner and non-owner changes in equity. Therefore, the consolidated statement of changes in equity will now include only details of transactions with owners. All non-owner changes in equity are presented as a single line labelled as total comprehensive income. The Standard also introduces the statement of comprehensive income: presenting all items of income and expense recognised in the income statement, together with all other items of recognised income and expense, either in one single statement, or in two linked statements. The Group has elected to show all items of income and expense in two linked statements. In addition, a statement of financial position is required at the beginning of the earliest comparative period following a change in accounting policy, the correction of an error or the reclassification of items in the financial statements. This revised FRS does not have any impact on the financial position and results of the Group.

The adoption of FRS 139 has resulted in the recognition of short term forward forex contracts at fair values classified as derivatives upon initial adoption. Subsequent changes to the fair values of the derivatives are recognized as other income or expense in the income statement.

2 Reclassification

On 15 March 2010, the Group's Investment in Associate, Maritzberg Investments Ltd., which holds 95% equity interest in PT Penta Valent ("PT PV") has been reclassified as available-for-sale financial asset following the resignation of the Group's sole corporate representative from the PT PV Board of Commissioners.

3 Audit report qualifications of the preceding annual financial statements

The Auditors had reported without any qualifications on the Group's audited financial statements for the year ended 31 December 2009.

4 Seasonality or cyclicity of interim operations

The Group's interim operations are not affected materially by any seasonal or cyclical factors.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER ENDED 30 JUNE 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 JUNE 2010 (continued)

5 Unusual items

There were no unusual items that affected the assets, liabilities, equity, net income or cash flows for the period ended 30 June 2010.

6 Changes in estimates of amounts reported in prior interim periods of the current financial year or in prior financial year

There were no changes in estimates of amounts reported in the prior interim periods of the current financial year or prior financial year.

7 Issuances, cancellations, repurchases, resale and repayments of debt and equity securities

During the current period, the Company increased its issued and paid up share capital from RM 74,973,500 to RM 93,716,875 by way of issuance of 18,743,375 new ordinary shares of RM 1.00 each credited as fully paid on the basis of one (1) bonus share for every four (4) existing ordinary shares of RM 1.00 each in the Company ("bonus issue"). The bonus issue was effected by way of wholly capitalizing the Company's share premium account of RM 5.31 million and retained earnings for the remainder of RM 13.44 million.

Other than the above, there were no issuance and/or repayment of debt and equity securities, share buy-backs, share cancellations, shares held as treasury shares and resale of treasury shares during the period ended 30 June 2010.

8 Dividends paid

The amount of dividends paid during the current and previous interim periods are as follows:

	30/06/2010	30/06/2009
	RM'000	RM'000
<u>In respect of the financial year ended 31 December</u>		
2009: Final Dividend of 4.5 sen gross per share less tax and Special Dividend of 10.0 sen gross per share less tax paid on 23-Jun-10	8,153	-
2008: Final Dividend of 4.5 sen gross per share less tax paid on 23-Jun-09	-	2,530
	<u>8,153</u>	<u>2,530</u>

9 Segment Information

The Group concluded that the reportable operating segments determined in accordance with FRS 8 are materially the same as the business segments previously identified under FRS 114 based on information that internally is provided to the Chief Executive Officer, who is the Group's chief operating decision maker.

OPERATING SEGMENTS	Manufacturing	Wholesale, marketing and distribution	Investment holding	GROUP
PERIOD ENDED 30/06/2010	RM'000	RM'000	RM'000	RM'000
Total Revenue	36,666	127,925	4,720	169,311
Inter-segment revenue	(10,795)	-	(3,865)	(14,660)
External Revenue	25,871	127,925	855	154,651
Segment Results (external)	10,478	6,643	(933)	16,188
Unallocated corporate expenses				(715)
Finance costs				(171)
Share of results of associate				1,373
Profit before tax				16,675
PERIOD ENDED 30/06/2009	RM'000	RM'000	RM'000	RM'000
Total Revenue	33,620	115,757	3,980	153,357
Inter-segment revenue	(9,474)	-	(3,685)	(13,159)
External Revenue	24,146	115,757	295	140,198
Segment Results (external)	8,462	4,195	(1,228)	11,429
Unallocated corporate expenses				(605)
Finance costs				(374)
Share of results of associate				1,072
Profit before tax				11,522
Segment assets				
30-Jun-2010	77,681	124,696	46,729	249,106
31-Dec-2009	71,518	119,012	46,067	236,597



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER ENDED 30 JUNE 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 JUNE 2010 (continued)

10 Valuations of Property, Plant and Equipment

The carrying value of land and buildings is based on a valuation carried out in the year ended 31 December 2009 by independent qualified valuers using the comparison and depreciated replacement cost methods to reflect their market value.

11 Significant Post Balance Sheet Events

On 28th July 2010, the Company acquired the entire share capital of Apex Retail Sdn Bhd ("ARSB"), formerly known as Supreme Eurostar Sdn Bhd, for a consideration of RM 2. Subsequently on 9th August 2010, ARSB subscribed for 120,000 ordinary shares at RM 1 per share representing 60% equity in the share capital of CS Health Store Sdn Bhd, a newly incorporated company whose principal activity is the retailing of pharmaceutical products, for a cash consideration of RM 120,000.

Other than the above, there were no significant events that had arisen subsequent to the end of this current period.

12 Changes in Group Composition

The Group did not undertake any business combinations, acquisitions or disposals of subsidiaries and long-term investments, restructuring or discontinuation of operations during the period ended 30 June 2010.

13 Changes in Contingent liabilities or Contingent assets.

There were no contingent liabilities or contingent assets of the Group since the end of the last annual balance sheet date except as disclosed in note 28.

14 Capital Commitments

Capital commitments of property, plant and equipment not provided for in the financial statements as at 30 June 2010 are as follows:

	RM'000
Authorised capital expenditure approved and contracted for	2,800
Authorised capital expenditure approved but not contracted for	2,456
	<u>5,256</u>

15 Related Party Transactions

There were no related party transactions during the period ended 30 June 2010.

16 Review of Performance

For the current quarter to June 2010, the Group's pretax profit was RM 7.8 million, an increase of 40% over that achieved in the similar quarter last year. Second quarter revenue reached RM 77.1 million, an increase of 10% over the same period in 2009. For the first six months of year 2010, the Group recorded a pretax profit of RM 16.7 million on revenue of RM 154.7 million, representing year-on-year growth of 45% and 10% respectively.

The Group's manufacturing division, Xepa-Soul Pattinson Malaysia Sdn Bhd, achieved 21% year-on-year revenue growth in the Malaysian private healthcare sector. Sales to retail pharmacies in Singapore were strong, and marketing activities in Vietnam were intensified so as to maintain growth momentum.

The wholesale, marketing and distribution division continued to sustain steady revenue growth, helped by strong sales of consumer healthcare products and new agency lines secured in the quarter. Margins were enhanced by a greater proportion of own brand products in the sales mix and careful control of operating expenses.

The Group's associate company in China, Xiamen Maidiken Science and Technology Co Ltd, continued to return strong results, with year-on-year revenue growth of 37%, driven largely by increased market share in pharmaceutical distribution and improved performance of its chain retail pharmacy operations.

17 Material changes in the profit before tax for the quarter

Profit before tax for the second quarter is 11% lower than that achieved in the immediate preceding quarter.

This is because of lower second quarter revenue compared to the first, attributed to a moderated demand for the Group's products following an exceptionally strong first quarter.

**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER ENDED 30 JUNE 2010
(THE FIGURES HAVE NOT BEEN AUDITED)****NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 JUNE 2010 (continued)**18 Commentary(a) Prospects

Consistent investment in manufacturing technology has been complemented by further strengthening of the sales and marketing force and export initiatives. A strong balance sheet, resulting from close attention to cash and inventory management places the Group in an excellent position to take advantage of opportunities that may arise.

Notwithstanding uncertainties about general economic recovery, the Board expects the Group's performance for the remaining six months of 2010 to be satisfactory barring unforeseen circumstances.

(b) Progress to achieve forecast revenue or profit estimate

Not applicable.

19 Statement by the Board of Directors' opinion on the achievability of forecast revenue or profit estimate

Not applicable.

20 Profit Forecast /Profit Guarantee

Not applicable.

21 Income Tax Expense

	3 MONTHS ENDED		PERIOD ENDED	
	30/06/2010	30/06/2009	30/06/2010	30/06/2009
	RM'000	RM'000	RM'000	RM'000
In respect of current period:				
income tax	1,830	848	3,517	2,471
deferred tax	(52)	180	191	213
others	-	-	-	-
	<u>1,778</u>	<u>1,028</u>	<u>3,708</u>	<u>2,684</u>
In respect of prior period:				
income tax	-	1	-	1
deferred tax	-	-	-	-
	<u>1,778</u>	<u>1,029</u>	<u>3,708</u>	<u>2,685</u>

The effective tax rate for the current quarter and financial year-to-date was lower than the statutory tax rate principally due to the non-taxable profits contributed by the Group's associated company.

22 Sale of Unquoted Investments and/or Properties

There were no sale of unquoted investments and/or properties during the period ended 30 June 2010.

23 Quoted Securities

(a) There were no acquisitions or disposals of quoted securities during the period ended 30 June 2010.

(b) There were no quoted securities held as at 30 June 2010.

24 Status of Corporate Proposals

There were no corporate proposals announced but not completed as at 11th August 2010.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER ENDED 30 JUNE 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 JUNE 2010 (continued)

25 Group Borrowings and Debt Securities

	AS AT	
	30/06/2010	31/12/2009
	RM'000	RM'000
Short term bank borrowings		
Secured	127	255
Unsecured	2,268	2,543
Total	2,395	2,798
Long term bank borrowings		
Secured	64	64
Unsecured	7,745	8,879
Total	7,809	8,943
Bank borrowings denominated in foreign currency as at 30 June 2010:	SGD'000	RM'000
Singapore Dollars	78	191

The Group did not have any non-current debt securities denominated in Ringgit Malaysia or foreign currency as at 30 June 2010.

26 Derivatives

(a) The Group's derivatives as at 30 June 2010 are as follows -

Type of Derivatives	Contract / Notional Amount RM'000	Changes in Fair Value	
		Assets	Liabilities
		RM'000	RM'000
Currency Forward Contracts			
Less than 1 year			
Sale of goods	1,950		27
Purchase of goods	434	3	
Purchase of machinery	1,569	20	
	3,953	23	27

(b) The Group does not anticipate any market or credit risks arising from these derivatives.

(c) The cash requirements relating to these contracts is RM 3,953,000.

(d) There have been no changes since the end of the previous financial year in respect of the following:

(i) the types of derivative contracts entered into and the rationale for entering into such contracts, as well as the expected benefits accruing from these contracts;

(ii) the risk management policies in place for mitigating and controlling the risks associated with these derivative contracts; and

(iii) the related accounting policies.

27 Fair Value Changes of Financial Liabilities

As at 30 June 2010, the Group does not have any financial liabilities measured at fair value through profit or loss.

28 Material Litigation

Shah Alam High Court Writ of Summons between Memory Tech Sdn Bhd and Apex Pharmacy Marketing Sdn Bhd

Upon our application submitted by our solicitors, the High Court has agreed to strike out the writ of summons and statement of claim on 1st July 2010.

29 Dividends

(a) The Board of Directors is pleased to declare the payment of a tax-exempt interim dividend of 4.00 sen per share in respect of the financial year ending 31 December 2010, resulting in a total dividend to-date for the current financial year of 4.00 sen per share. (Year 2009: Interim taxable dividend of 5.25 sen gross per share).

(b) The date of the book closure for the interim dividend payment will be announced in due course.



APEX HEALTHCARE BERHAD (473108-T)

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER ENDED 30 JUNE 2010
(THE FIGURES HAVE NOT BEEN AUDITED)**

NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 JUNE 2010 (continued)

30 Earnings per share

		3 MONTHS ENDED		PERIOD ENDED	
		30/06/2010	30/06/2009	30/06/2010	30/06/2009
<u>Basic Earnings per share</u>					
Profit after tax	RM'000	5,800	4,216	12,504	8,445
Weighted average number of ordinary shares in issue	'000	93,717	74,974	93,717	74,974
Basic earnings per share	sen	6.19	5.62	13.34	11.26
<u>Diluted Earnings per share</u>					
Profit after tax	RM'000	5,800	4,216	12,504	8,445
Weighted average number of ordinary shares in issue	'000	93,717	74,974	93,717	74,974
Adjustment for share options	'000	-	-	-	-
Weighted average number of ordinary shares in issue for diluted earnings per share	'000	93,717	74,974	93,717	74,974
Diluted earnings per share	sen	6.19	5.62	13.34	11.26